Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Neuro Panel Will Review Cyberonics, Confluent Postmarket Data

This article was originally published in The Gray Sheet

Executive Summary

FDA's Neurological Devices Panel will consider post-approval study data for Cyberonics' implantable VNS Therapy for treatment-resistant depression and for Tyco/Confluent Surgical's DuraSeal cranial surgery sealant system Jan. 26, FDA announced Dec. 22

You may also be interested in...



FDA Panel Gives Thumbs Up To DuraSeal Xact Spine Surgery Sealant

Covidien's DuraSeal Xact dural repair sealant for spine surgery should be approved with conditions, FDA's Neurological Devices panel recommended in a unanimous 4-0 vote May 14

FDA Panel Gives Thumbs Up To DuraSeal Xact Spine Surgery Sealant

Covidien's DuraSeal Xact dural repair sealant for spine surgery should be approved with conditions, FDA's Neurological Devices panel recommended in a unanimous 4-0 vote May 14

FDA Aims To Up Transparency By Making Panel Materials Public Sooner

FDA will post advisory committee briefing materials on its Web site at least two business days in advance of meetings, doubling the current lead time in an effort to enhance transparency, according to a 1draft guidance released last week

Related Content

UsernamePublicRestriction

Register

OM004967

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel